Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard
Adverse events should also be reported to the Ipsen Medical Information Department on +44(0) 1753 627777 or pharmacovigilance.uk-ie@ipsen.com
A link to the prescribing information can be found in the header.
Information for your patients who may be starting their androgen deprivation treatment (ADT) journey with Decapeptyl® SR (triptorelin) or who are considering changing to Decapeptyl® SR (triptorelin).
This guide is intended only for men prescribed LHRHa treatment for prostate cancer with Decapeptyl® SR. It is designed to help men understand their prostate cancer treatment and how to get the most from it.
The guide is written in a clear question and answer format and covers:
The guide also includes space for patients to record their PSA levels and LHRHa injection appointments to keep track of their treatment.
This guide is intended only for men prescribed LHRHa treatment for prostate cancer with Decapeptyl® SR. It provides information for patients moving from another LHRHa (referred to as GnRHa in the guide) to Decapeptyl® SR.
The guide is written in a clear question and answer format and covers:
‘Let’s Talk About the Hard Things’ is a patient awareness campaign developed by Ipsen in partnership with Prostate Cancer Research.
The campaign was based on the findings of a Ipsen-sponsored patient survey that was designed to better understand the experiences faced by men living with prostate cancer, particularly in terms of the challenges that may arise from the side effects of treatments such as radical prostatectomy, radiotherapy and ADT.
The campaign aims to not only break down the taboos surrounding possible side effects of prostate cancer treatment but also encourage men to talk about their experiences with friends, family, and healthcare professionals.
